Summit surges after AstraZeneca makes $2 billion equity investment
BUZZ-Summit surges after AstraZeneca makes $2 billion equity investment ** Shares of Summit Therapeutics SMMT.O up 18% at $18.2 in extended trading
** AstraZeneca AZN.L will make a $2 billion equity investment in Summit through convertible preferred shares
** Says investment is convertible into common stock at $18.36 per share, representing a premium to the day's closing price
** Co and AstraZeneca entered into a clinical collaboration to evaluate ivonescimab in combination with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers
** Says it plans to evaluate ivonescimab with additional AstraZeneca cancer medicines, including antibody-drug conjugates
** Co says AstraZeneca's investment is expected to close by the end of the week, subject to customary conditions
** Up to last close, SMMT down 11.5% YTD
(Reporting by Varun Sahay in Bengaluru)
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)